

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Dose Optimization and Scarce Resource Allocation: Two Sides of the Same Coin

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-063436.R1
Article Type:	Communication
Date Submitted by the Author:	27-Apr-2022
Complete List of Authors:	Strohbehn, Garth; VA Center for Clinical Management Research, Persad, Govind; University of Denver, Parker, William; University of Chicago Department of Medicine Murthy, Srinivas; University of British Columbia, Paediatrics
<b>Primary Subject Heading</b>:	Global health
Secondary Subject Heading:	Ethics, Health services research, Infectious diseases, Pharmacology and therapeutics, Public health
Keywords:	CLINICAL PHARMACOLOGY, Clinical trials < THERAPEUTICS, MEDICAL ETHICS, COVID-19, Public health < INFECTIOUS DISEASES, Rationing < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Dose Optimization and Scarce Resource Allocation: Two Sides of the Same Coin

Garth W Strohbehn, MD, MPhil<sup>1,2</sup>

Govind Persad, JD, PhD<sup>3</sup>

William F Parker, MD, PhD<sup>4,5</sup>

Srinivas Murthy, MDCM, MHSc<sup>6</sup>

<sup>1</sup>Veterans Affairs Ann Arbor Medical Center, Center for Clinical Management and Research and <sup>2</sup>Rogel Comprehensive Cancer Center, University of Michigan Medicine, both in Ann Arbor, MI, USA; <sup>3</sup>University of Denver, Sturm College of Law, Denver, CO, USA; <sup>4</sup>Section of Pulmonary and Critical Care Medicine and <sup>5</sup>Maclean Center for Medical Ethics, University of Chicago, Chicago, IL, USA; and <sup>6</sup>Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada

**Journal:** *BMJ Open*

**Article Type:** Communication

**Article ID:** bmjopen-2022-063436

**Previous BMJ Manuscript ID:** bmj-2021-067208

**Correspondence to:**

Garth W Strohbehn, MD, MPhil

Veterans Affairs Center for Clinical Management and Research

North Campus Research Center, B16-322W

Ann Arbor, MI 48105 USA

Email: gstrohbe@umich.edu

**Word count:** 2673

**References:** 30

## 1      1      **Key Messages**

- 2      2      ● Drug scarcity reflects gross mismatch between supply and demand; societies strive to allocate
- 3      3      scarce resources allocated in a manner that reflects their values
- 4      4      ● A deep understanding of the relationship between a scarce drug's dose and clinical response is
- 5      5      necessary to appropriately distribute a supply-constrained drug
- 6      6      ● Future pandemic clinical trials should obtain dose optimization data in order to enable
- 7      7      appropriate distribution

## 8      8      9      9      **Declarations**

10      10      Ethics approval and consent to participate: Not applicable

11      11      Consent to publish: Not applicable

12      12      Availability of data and materials: Not applicable

13      13      Competing interests: GWS is an employee of the US Government; the views expressed are his own and

14      14      do not necessarily represent those of the Department of Veterans Affairs or US Government. GWS is a

15      15      listed co-inventor of a filed patent held by the University of Chicago covering the use of low-dose

16      16      tocilizumab in viral infections. GWS and SM have served in World Health Organization Clinical

17      17      Therapeutics Working Groups; the views expressed are theirs and do not reflect the World Health

18      18      Organization or other members of Working Groups.

19      19      Funding: This research received no specific grant from any funding agency in the public, commercial or

20      20      not-for-profit sectors.

21      21      Authors' Contributions: Concept and Design: All authors. Analysis of the Literature: All authors. Drafting

22      22      of the Manuscript: GWS. Critical revision of the manuscript for important intellectual content: All

23      23      authors.

24      24      Acknowledgments: None.

## 25      25      26      26      **Contributors and sources**

27      27      GWS is a clinical trialist and health services researcher whose work centers on dose-optimization to

28      28      combat drug scarcity and financial toxicity. He is a contributor to the World Health Organization's Rapid

29      29      Evidence Appraisal for COVID-19 Therapies. GP is a bioethicist and health law researcher. He has

30      30      participated in a rapid expert consultation for the National Academies of Sciences, Engineering, and

31      31      Medicine (USA) on COVID-19 therapeutic allocation. WFP is an intensivist and bioethicist whose work

32      32      centers on scarce resource allocation. He chairs his institution's COVID-19 Ethics Resource group. SM is

33      33      an intensivist and infectious disease physician. He is a co-investigator of REMAP-CAP and is the co-chair

34      34      of the WHO Clinical Characterization and Management research committee for COVID-19.

## 35      35      36      36      **Patient involvement**

37      37      No patients were involved in the planning or conduct of this work.

## Dose Optimization and Scarce Resource Allocation

### **Abstract**

Drug scarcity reflects gross mismatch between supply and demand. Under conditions of scarcity, societies strive to allocate scarce resources in a manner that best reflects their values, whatever they may be. Maximizing benefits and reducing inequities are two major values that guide allocation decisions. A deep understanding of the relationship between a scarce drug's dose and clinical response is necessary to appropriately distribute a supply-constrained drug along these lines. The vast majority of drug development and repurposing during the COVID-19 pandemic – an event that has made clear the ever-present scarcity in healthcare systems – has been ignorant of scarcity and dose optimization's ability to help address it. Future pandemic clinical trials systems should obtain dose optimization data, as these appear necessary to enable appropriate scarce resource allocation according to societal values.

**Keywords:** global health, public health, medical ethics, clinical trials

## 1 Background

2 Absolute scarcity – when demand for a resource vastly exceeds a limited supply – has been a recurring  
3 theme of the COVID-19 pandemic.<sup>1</sup> Under absolute scarcity, resource allocation is inevitably zero sum.  
4 Increasing supply of an absolutely scarce resource through increased production is one approach, but  
5 this may not be feasible (scientifically or politically) over the timescale required to nimbly and effectively  
6 respond to scarcity for certain resources.<sup>2</sup> Societies must then confront these tragic situations imposed  
7 by allocating absolutely scarce resources in a manner that reflects their values, whatever those values  
8 may be.<sup>3</sup> In a strained health environment, many countries will seek to allocate scarce medical  
9 interventions in a manner that balances benefit maximization with inequity minimization. Doing so  
10 requires first knowing how much of the absolutely scarce resource is available, and second, knowing  
11 how much benefit recipients can expect to gain from each additional unit of the resource received. This  
12 second, key piece of information requires an understanding of the relationship between the scarce  
13 resource's dose and clinical efficacy.<sup>4</sup>

14 A resource's ability to benefit individuals and populations depends on its abundance or scarcity.  
15 For resources that are *not* abundant, tradeoffs between the relative welfares of individuals and  
16 populations become inevitable.<sup>2</sup> These tradeoffs become especially acute when considering the  
17 absolute scarcity of medical resources during a pandemic.

18 The conventional drug development paradigm is oriented toward the individual, assuming  
19 abundance with neither limitation on access nor tradeoffs between recipients. Critically, to the  
20 individual who is eligible to receive a given candidate therapy in the context of a clinical trial, that  
21 therapy is itself abundant. The resulting dosing regimen, then, does not impact other potential  
22 recipients' access. Dose-finding and efficacy studies strive to maximize the net benefit for each  
23 individual recipient of the candidate therapy. In the context of an early phase clinical trial (of an  
24 abundant drug), administering more than the minimum amount needed to achieve maximum benefit  
25 presents no issue, so long as the additional amount does not increase harms.

26 The abundance assumption implied by conventional drug development falters under scarcity.  
27 Drug resources, including those that appear abundant before a disaster hits,<sup>5,6</sup> can quickly become  
28 absolutely scarce. When absolute scarcity emerges – with its attendant tradeoffs – administration of  
29 excessive amounts of drug reduces total benefits by excluding potential recipients, and exacerbates  
30 inequities between those with access and those without.<sup>7</sup> In truth, an infinite number of dose levels are  
31 theoretically possible for a given drug. For physicians and policymakers navigating scarcity dosing of an

1 absolutely scarce resource is an optimizable choice – but it requires re-approaching dosing with a  
2 scarcity mindset.

#### 3 4 **Main Text**

##### 5 *Selected Dose Levels in COVID-19*

6 On the basis of demonstrated clinical benefit, 13 drugs (including vaccines) have been approved or  
7 authorized by high-income governments for the treatment or prevention of COVID-19 as of October 1,  
8 2021, with still more in development.<sup>8</sup> Dosing uncertainty persists for each (**Table 1**), in turn reducing  
9 health system capacity, efficiency of supply utilization, and population health. To better understand the  
10 specific dose level that we ought to target in pandemic drug development, however, it is useful to  
11 review the dose levels that have been chosen thus far.

##### 12 13 *Labeled Dose for Prior Indication*

14 The dosages of drugs repurposed for treatment of COVID-19 have almost uniformly duplicated those in  
15 the drug's original, pre-COVID-19 indication (**Table 1**). Prior clinical information provides investigators  
16 with the pharmacokinetic and safety information needed to rapidly incorporate a candidate drug into a  
17 clinical trial, bypassing traditional front-end dose-finding.<sup>9</sup> In such a trial, if the dose used for the original  
18 indication *exceeds* the minimum dose needed to demonstrate efficacy in COVID-19, then investigators  
19 are able to determine whether the drug is efficacious in COVID-19. The speed conferred by bypassing  
20 front-end dose-finding benefits patients through earlier identification of efficacious drugs. But this  
21 strategy, by not attempting to identify an optimal dose for the drug in COVID-19 introduces two major  
22 risks: First, that, because of relative *underdosing*, a clinical trial may reach a false negative conclusion  
23 about the drug's efficacy and second, that the appropriate dose for one indication is in truth excessive  
24 for COVID-19, exacerbating scarcity and potentially resulting in excess harms (neither of which are  
25 knowable at trial initiation).

##### 26 27 *Model-Informed Drug Repurposing*

28 Model-informed drug repurposing (MIDR) uses *in vitro* estimates of a repurposed drug's activity against  
29 a novel pathogen, such as COVID-19, to guide initial anti-infective dosing. As a pathogen is better  
30 characterized during the course of a pandemic, investigators can connect pharmacokinetics to  
31 epidemiologic modeling, enabling clinical trials to administer the (presumed) right dose of therapy at the  
32 right time, enhancing the odds of demonstrating efficacy if it truly exists.<sup>10</sup> Importantly, however, the



1  
2  
3 1 small molecule antiviral drugs for which MIDR has been employed have not been shown to reduce  
4 COVID-19-related mortality.<sup>11</sup> In the COVID-19 pandemic, the pathogen-directed approaches that  
5 reduce mortality have uniformly been new chemical entities.<sup>12 13</sup> Coupled with MIDR's requirement for  
6 *in vitro* assay development and validation to guide dosing decisions, the benefits of host-targeted  
7 therapies,<sup>14</sup> and the speeds with which novel antibody-based antiviral and mRNA vaccine development  
8 can occur, MIDR may be ill-suited to both rapid and accurate action in future viral pandemics.  
9  
10  
11  
12  
13  
14

### 15 8 *Dosing Informed by Randomized, Dose-Ranging Trials*

16 9 Randomized, placebo-controlled dose-ranging studies directly compare multiple dose levels (including  
17 placebo) to one another to identify signs of clinical activity and the extent to which a dose-response  
18 relationship exists. These trials are often conducted in phase 2, *before* confirmatory efficacy trials.  
19 Timing is critical: Randomized, placebo-controlled dose-ranging studies evaluating key clinical endpoints  
20 can enable dosing that responds to emergency conditions. For example, the BLAZE-1 trial evaluated  
21 whether any of three different doses (700mg, 2800mg, 7000mg) of bamlanivimab reduced SARS-CoV-2  
22 viral load.<sup>15</sup> Despite only the 2800mg arm reducing SARS-CoV-2 viral load, the 700mg dose was granted  
23 Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration due to its comparable  
24 reduction in emergency care utilization and hospitalization – instantaneously providing a many-fold  
25 increase in the number of patients who could benefit from a limited supply.  
26  
27  
28  
29  
30  
31  
32  
33

34 19 More disappointing for global health advocates, however, has been an absence of urgency in  
35 pursuing SARS-CoV-2 vaccine dose optimization. For example, half-dose (50µg) mRNA-1273 generates  
36 SARS-CoV-2-neutralizing antibodies and seroconversion at rates nearly equivalent to full dose, with all  
37 half-dose recipients in the trial seroconverting by six weeks after the first dose.<sup>16</sup> Similar findings have  
38 been suggested for the BNT162b2 mRNA vaccine.<sup>17</sup> Similarly, quarter-dose (25µg) mRNA-1273 is  
39 sufficient to generate durable cellular immunity against SARS-CoV-2.<sup>18</sup> As it relates to boosters, dose-  
40 finding studies might even allow for a massive reduction in vaccine supply utilization while minimizing  
41 risk of adverse events.<sup>19</sup> Yet this concept has not been pursued in follow-up trials, despite the potential  
42 to instantaneously increase access at least 2-4 fold while simultaneously reducing the likelihood of  
43 adverse events, especially in the adolescent and young adult subpopulations at risk for vaccine-related  
44 myocarditis.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 Potential Dose Levels for Future Pandemic Drug Development

2 The extent to which a pandemic drug's dose is ideal depends on the lens through which one views the  
3 allocation problem. Optimizing dose to population health versus that of the individual can lead to very  
4 different dosing decisions. Two approaches to dosing are described below.

### 5 6 *Minimum Dose with Satisfactory Efficacy*

7 The minimum dose with satisfactory efficacy (MDSE) approach pre-defines a satisfactory level of efficacy  
8 and then identifies the minimum amount of drug needed to achieve that level, based on the dose-  
9 response information provided by dose-ranging studies.<sup>20</sup> The MDSE approach is best suited for a clinical  
10 context in which a drug is *known* to have efficacy when administered at a given dose, frequency, route  
11 of administration, and duration. Downsides to the MDSE-focused approach include the time needed to  
12 optimize the drug's dose and the suboptimal efficacy likely to be experienced by at least one dose  
13 cohort in a clinical trial in order to identify the MDSE. Low-dose tocilizumab<sup>21</sup> and pre-clinical attempts  
14 toward mRNA vaccine dose minimization are examples of attempted MDSE identification during the  
15 COVID-19 pandemic.<sup>16 18</sup> MDSE-based drug development operates from a socially-minded yet individual-  
16 dominant perspective, wherein the arrived upon MDSE depends upon one's definition of "satisfactory".

### 17 18 *Socially Optimal Dose*

19 The socially optimal dose (SOD) is still more socially-minded. SOD is the theoretical dose at which  
20 individual efficacy-per-unit is maximized (**Figure 1**). Utilization of the SOD sacrifices maximal efficacy for  
21 each recipient in order to increase population-level benefit by increasing the number of recipients.<sup>4</sup> The  
22 SOD, derived from estimates of the population-level dose-response relationship, attempts to maximize  
23 the quantity of benefit the drug produces without regard to distribution, and may facilitate allocation  
24 strategies that focus solely on maximizing population-level efficacy. One real-world example of (more)  
25 socially optimal dosing – outside the bounds of a clinical trial – was the use of extended-interval dosing  
26 of mRNA vaccines, in which the potential risk of worsened individual-level outcomes due to the  
27 extended dose interval was accepted in exchange for the potential benefit of protecting more people,  
28 acknowledging recipients may receive sub-optimal protection by straying from the evidence base.<sup>22 23</sup> In  
29 retrospect, although this was a successful calculated risk, testing the strategy prospectively would have  
30 been preferred.<sup>24-26</sup>

31

### 1 Strategic Pandemic Clinical Trial Systems for the Future

2 Under the relative abundance present outside a pandemic, once an efficacious therapy is identified,  
3 clinical trialists most commonly turn their attention to the *next* candidate drug – for example, by asking  
4 “*Can addition of a new therapy improve a given individual’s outcome?*” However, from a population  
5 health perspective, the key question often is “*How do we, as a health system, maximize the benefits*  
6 *generated by this therapy’s finite supply?*”

7 During a pandemic, however, conscientious policymakers will often adopt strategies that  
8 allocate scarce resources according to societal values, including toward maximization of benefit and  
9 reduction of inequities.<sup>3</sup> Simulations of vaccine allocation in which lives saved is the primary outcome,<sup>17</sup>  
10 as well as real-world evidence,<sup>24 25</sup> demonstrate the necessity of knowing in real-time the dose-efficacy  
11 relationship and an approach that aligns with allocation of scarce resource based on SOD. Either MDSE-  
12 or SOD-based allocation schemas would be well-suited to navigating pandemic-fueled drug scarcity in  
13 order to improve population health, but their derivation may require dose-ranging clinical trials. How,  
14 then, to incorporate dose-optimization studies and enable welfare maximization more efficiently in the  
15 future?

16 Incorporation of dose-optimization studies into platform trials is a next step toward maximizing  
17 population health, and the answer likely resides in blended trials that combine efficacy assessment with  
18 dose-optimization. Employed at scale, platform trials have allowed for rapid identification of efficacious  
19 repurposed therapies through simultaneous evaluation of multiple candidate drugs.<sup>9</sup> Therefore, a two-  
20 step approach in which efficacy is first determined in a platform trial, followed immediately by  
21 randomized, dose-ranging studies aimed at dose optimization (perhaps guided by surrogate endpoints  
22 derived from the earlier, larger definitive RCTs) can provide physicians and policymakers with the  
23 information needed to best allocate scarce resources toward population health aims. Seamless clinical  
24 trial designs proceeding from dose-finding to efficacy assessment have previously been conducted.<sup>27 28</sup>  
25 Given the need to rapidly begin generating benefits, a future pandemic research paradigm should begin  
26 first with an assessment of a drug’s potential to generate benefits for an individual patient, followed by  
27 a thorough exploration of the dose-efficacy relationship to inform optimal allocation.

### 28 29 Considerations for Trialists, Health Systems, and Policymakers

30 Incorporation of dose optimization of scarce medical resources is not without its challenges or criticisms.  
31 First, clinicians, researchers, and participants must be convinced that the risk to an individual involved in  
32 a dose-optimization trial is reasonable, when viewed in relation to the social value that the trial

1 provides. Individuals enrolled in dose-optimization studies ultimately bear the risks of these trials. Chief  
2 among these is the risk that the lower dose has lower efficacy than the previously tested dose, a risk  
3 that can be mitigated by allowing for crossover. Counterintuitive *benefits* may emerge: Lower doses may  
4 have improved safety profiles and individuals enrolling in dose-optimization trials may receive access to  
5 therapies earlier than those who do not. Individuals enrolled in dose-optimization trials may therefore,  
6 on balance, *benefit* from the lower dose – while also contributing to potentially substantial population  
7 benefit. While the populations to which MDSE and SOD will apply are more heterogeneous than the  
8 population in which a dose-ranging clinical trial is conducted, a dose-ranging study would be a  
9 potentially high-reward incremental step.

10         Second, critics may worry that dose optimization will lengthen development, repurposing, and  
11 authorization or approval timelines, or unnecessarily *increase* the rate at which stockpiles of absolutely  
12 scarce drugs are used. Dose optimization indeed requires time, but simulation and real-world studies  
13 suggest it can enable implementation strategies that save more lives.<sup>4 17 24-26</sup> Two-staged result reporting  
14 – efficacy trial result first, followed by dose optimization – may allow patients to benefit from a therapy  
15 with demonstrated efficacy while dose optimization efforts are ongoing. Unpredictable supply chains  
16 and increased demand leave clinicians and patients to grapple with a fundamental question “Is it worth  
17 the risk *to this patient*, who has access to the scarce medicine, to potentially provision a lower dose?”  
18 Within the individual doctor-patient relationship, public health arguments lack an advocate, resulting in  
19 an answer of “No.” Health authorities and regulators must make efforts to ensure adequate drug supply  
20 for dose optimization clinical trials, and hospital authorities should cordon off supplies for dose  
21 optimization trials that may serve the greater good.

22         Third, the successes of corticosteroids in COVID-19 might suggest avoiding the need for dose  
23 optimization by limiting our efforts to abundant therapies. This line of thinking represents supply-  
24 consciousness but has strategic flaws: It limits the universe of potential therapies that can be tested, no  
25 matter how well-reasoned mechanistically; fails to anticipate that a therapy being studied could become  
26 scarce in the future; and neglects geographic heterogeneity in abundance/scarcity. Extending the  
27 supplies of relatively abundant drugs *in the event of higher than anticipated demand* is consistent with a  
28 benefit-maximizing, inequity-minimizing strategy. Moreover, failing to reconsider the dose of abundant  
29 drugs risks *under-dosing* and failure to capture population benefits that otherwise could have been  
30 achieved.

31         Some may contend that lower doses should not be used until clinical efficacy is established in a  
32 confirmatory clinical trial comparing low-dose to standard-dose, implying that development timelines

1  
2  
3 1 will be lengthened. While of course a reasonable concern, risk calculus is contextual. Whether to adopt a  
4  
5 2 lower dose of an absolutely scarce therapy based on suboptimal evidence must be decided in awareness  
6  
7 3 of the dangers resulting from ongoing absolute scarcity. Expanding population access to a therapy by  
8  
9 4 lowering the dose – even if doing so sacrifices some degree of individual-level efficacy – may be socially  
10  
11 5 optimal, ethical, and in line with the goals of a given society.<sup>4 29</sup> Generation of this information alone  
12  
13 6 does not compel policymakers to action.

13 7 Last, some may worry that dosing strategies that aim to promote population health treat  
14  
15 8 *individual* recipients inequitably, by providing a dose that is less beneficial than the dose that would be  
16  
17 9 provided under abundance. But, under scarcity, maintaining the dosing strategies used under  
18  
19 10 abundance may exclude many who can benefit. Maximizing benefits for a few recipients while leaving  
20  
21 11 many unprotected for want of access is likely to neither maximize population welfare nor serve a  
22  
23 12 society's equity goals. Indeed, a dose-optimized approach to scarce medicines may facilitate fulfillment  
24  
25 13 of rational pharmacotherapy's goal of ensuring therapeutically sound and cost-effective use of  
26  
27 14 medicines in a post-COVID-19 world.

## 16 16 **Conclusions**

17 17 Maximizing the benefits generated by limited drug supplies due to a scarcity of information. Clinical care  
18  
19 18 under scarcity and clinical care under abundance are different. Research questions and the clinical trials  
20  
21 19 used to answer them must acknowledge this reality in order to serve population health goals.  
22  
23 20 Policymakers must make strategic decisions, and medicine's role is to provide the information that  
24  
25 21 guides these decisions. Dosing remains a major inefficiency to be improved upon during the COVID-19  
26  
27 22 pandemic. In a post-COVID-19 future, these issues are likely to persist *after* the COVID-19 pandemic for  
28  
29 23 high-cost cancer and rheumatology drugs in low- and middle-income countries.<sup>29 30</sup> Clinical trial systems,  
30  
31 24 supported by policy-makers, must acknowledge scarcity and take appropriate steps to optimize dosing.  
32  
33 25 Though methodologic questions remain, a two-step model of innovation that recognizes the inherent  
34  
35 26 tension between population health and individual health under scarcity is one potential approach  
36  
37 27 moving forward.  
38  
39 28  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 List of Abbreviations**

4  
5 **2 COVID-19:** Novel coronavirus disease 2019

6  
7 **3 EUA:** Emergency Use Authorization

8  
9 **4 MDSE:** Minimum dose with satisfactory efficacy

10  
11 **5 MIDR:** Model-informed drug repurposing

12  
13 **6 MRNA:** Messenger ribonucleic acid

14  
15 **7 RCT:** Randomized, controlled trial

16  
17 **8 SARS-CoV-2:** Severe acute respiratory syndrome coronavirus 2

18  
19 **9 SOD:** Socially optimal dose

## 1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28           29           30           31           32           33           34           35           36           37           38           39           40           41           42           43           44           45           46           47           48           49           50           51           52           53           54           55           56           57           58           59           60

1. Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. *N Engl J Med* 2020;382(20):1873-75. doi: 10.1056/NEJMp2005492 [published Online First: 2020/03/18]
2. Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical interventions. *Lancet* 2009;373(9661):423-31. doi: 10.1016/S0140-6736(09)60137-9
3. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *N Engl J Med* 2020 doi: 10.1056/NEJMs2005114 [published Online First: 2020/03/23]
4. Strohbehn GW, Parker WF, Reid PD, et al. Socially optimal pandemic drug dosing. *The Lancet Global Health* 2021 doi: 10.1016/S2214-109X(21)00251-5
5. Águas R, Mahdi A, Shretta R, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. *Nat Commun* 2021;12(1):915. doi: 10.1038/s41467-021-21134-2 [published Online First: 2021/02/10]
6. Administration FaD. FDA Drug Shortages - Dexamethasone Sodium Phosphate Injection 2021 [Available from: [https://www.accessdata.fda.gov/scripts/drugshortages/dsp\\_ActiveIngredientDetails.cfm?AI=Dexamethasone%20Sodium%20Phosphate%20Injection&st-ct&tab=tabs-1#](https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexamethasone%20Sodium%20Phosphate%20Injection&st-ct&tab=tabs-1#) accessed February 3 2021.
7. Kruk ME, Gage AD, Arsenault C, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. *Lancet Glob Health* 2018;6(11):e1196-e252. doi: 10.1016/S2214-109X(18)30386-3 [published Online First: 2018/09/05]
8. Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. *Nat Rev Drug Discov* 2021 doi: 10.1038/d41573-021-00037-3 [published Online First: 2021/02/25]
9. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. *JAMA* 2015;313(16):1619-20. doi: 10.1001/jama.2015.2316
10. Dodds MG, Krishna R, Goncalves A, et al. Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. *Br J Clin Pharmacol* 2020 doi: 10.1111/bcp.14486 [published Online First: 2020/07/21]
11. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med* 2021;384(6):497-511. doi: 10.1056/NEJMoa2023184 [published Online First: 2020/12/02]
12. RECOVERY. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv, 2021.
13. Bariola JR, McCreary EK, Wadas RJ, et al. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection. *Open Forum Infectious Diseases* 2021 doi: 10.1093/ofid/ofab254
14. Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* 2020 doi: 10.1001/jama.2020.17023 [published Online First: 2020/09/02]

- 1 15. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients  
2 with Covid-19. *N Engl J Med* 2021;384(3):229-37. doi: 10.1056/NEJMoa2029849  
3 [published Online First: 2020/10/28]
- 4 16. Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2  
5 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine* 2021  
6 doi: <https://doi.org/10.1016/j.vaccine.2021.02.007>
- 7 17. Jurgens G. Low dose regimens of BNT162b2 mRNA vaccine exceed SARS-Cov-2 correlate of  
8 protection estimates for symptomatic infection, in those 19-55 years of age. medRxiv,  
9 2021.
- 10 18. Mateus J, Dan JM, Zhang Z, et al. Low-dose mRNA-1273 COVID-19 vaccine generates  
11 durable memory enhanced by cross-reactive T cells. *Science* 2021:eabj9853. doi:  
12 10.1126/science.abj9853 [published Online First: 20210914]
- 13 19. Strohbehn GW, Parker WF, A T. What's the right dose for COVID boosters?  
14 MedPageToday2021 [Available from: [https://www.medpagetoday.com/opinion/second-](https://www.medpagetoday.com/opinion/second-opinions/94500)  
15 [opinions/94500](https://www.medpagetoday.com/opinion/second-opinions/94500) accessed October 1 2021.
- 16 20. Lesko LJ, Rowland M, Peck CC, et al. Optimizing the science of drug development:  
17 opportunities for better candidate selection and accelerated evaluation in humans. *J*  
18 *Clin Pharmacol* 2000;40(8):803-14. doi: 10.1177/00912700022009530
- 19 21. Strohbehn GW, Heiss BL, Rouhani SJ, et al. COVIDOSE: A phase 2 clinical trial of low-dose  
20 tocilizumab in the treatment of non-critical COVID-19 pneumonia. *Clin Pharmacol Ther*  
21 2020 doi: 10.1002/cpt.2117 [published Online First: 2020/11/18]
- 22 22. Wiecek W, Ahuja A, Chaudhuri E, et al. Testing fractional doses of COVID-19 vaccines. *Proc*  
23 *Natl Acad Sci U S A* 2022;119(8) doi: 10.1073/pnas.2116932119 [published Online First:  
24 2022/02/09]
- 25 23. Saad-Roy CM, Morris SE, Metcalf CJ, et al. Epidemiological and evolutionary considerations  
26 of SARS-CoV-2 vaccine dosing regimes. *Science* 2021;372(6540):363-70. doi:  
27 10.1126/science.abg8663 [published Online First: 20210309]
- 28 24. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19  
29 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national  
30 prospective cohort study. *Lancet* 2021 doi: 10.1016/S0140-6736(21)00677-2 [published  
31 Online First: 2021/04/23]
- 32 25. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in  
33 England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a  
34 prospective, multicentre, cohort study. *Lancet* 2021 doi: 10.1016/S0140-6736(21)00790-  
35 X [published Online First: 2021/04/23]
- 36 26. Romero-Brufau S, Chopra A, Ryu AJ, et al. Public health impact of delaying second dose of  
37 BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.  
38 *BMJ* 2021;373:n1087. doi: 10.1136/bmj.n1087 [published Online First: 2021/05/12]
- 39 27. Laterre PF, Berry SM, Blemings A, et al. Effect of Selepressin vs Placebo on Ventilator- and  
40 Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized  
41 Clinical Trial. *JAMA* 2019;322(15):1476-85. doi: 10.1001/jama.2019.14607
- 42 28. Berry SM, Spinelli W, Littman GS, et al. A Bayesian dose-finding trial with adaptive dose  
43 expansion to flexibly assess efficacy and safety of an investigational drug. *Clin Trials*



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1           2010;7(2):121-35. doi: 10.1177/1740774510361541 [published Online First:  
2           2010/03/25]  
3           29. Persad GC, Emanuel EJ. The ethics of expanding access to cheaper, less effective  
4           treatments. *Lancet* 2016;388(10047):932-4. doi: 10.1016/S0140-6736(15)01025-9  
5           [published Online First: 2016/04/20]  
6           30. Serritella AV, Strohbehn GW, Goldstein DA, et al. Interventional Pharmacoeconomics: A  
7           Novel Mechanism for Unlocking Value. *Clin Pharmacol Ther* 2020 doi: 10.1002/cpt.1853  
8           [published Online First: 2020/04/16]

For peer review only

1  
2  
3 **1 Table and Figure Legends**  
4 **2**

5 **3 Table 1. Dose optimization of repurposed and new molecular entities for SARS-CoV-2 and COVID-19 as of**  
6 **4 Summer 2021.** Drugs that have received regulatory approval or authorization, as well as U.S. guideline-  
7 **5** recommended drugs, for the prevention or treatment of COVID-19 are summarized in the table. From left to right,  
8 **6** columns demonstrate minimal pre-RCT dose-finding in COVID-19, a limited number of welfare-maximizing dose  
9 **7** optimization trials, and the absence of any MDSE identification in COVID-19 therapeutics. **Abbreviations:** RCT,  
10 **8** randomized, controlled trial; MDSE, minimum dose with satisfactory efficacy; IL-6, interleukin-6; CAR-T CRS,  
11 **9** chimeric antigen T-cell receptor-related cytokine release syndrome; EMA, European Medicines Agency; JAK, Janus  
12 **10** kinase; STAT, signal transducer and activator of transcription proteins; ARDS, acute respiratory distress syndrome.  
13

14 **11**  
15 **12 Figure 1. Distinctions between individually and socially optimal dosing approaches for a hypothetical vaccine. (A)**  
16 **13** A randomized dose-finding study reveals the dose-response curve shown, where a vaccine is found to have  
17 **14** maximal efficacy at a 100mcg dose and approximately 75% relative efficacy at quarter-dose. (B) By evaluating the  
18 **15** drug's efficacy relative to the amount of drug administered, we derive the socially optimal dose, maximizing the  
19 **16** efficacy gained per microgram administered. Abbreviations: MDSE, minimum dose with satisfactory efficacy; RCT,  
20 **17** randomized, controlled trial.  
21 **18**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

158x237mm (150 x 150 DPI)

<i>Drug (Manufacturer)</i>	<i>Dedicated COVID-19 Dose-Finding Study</i>	<i>Post-RCT Dose Optimization or Supply Expansion Clinical Trial</i>	<i>Defined Dose- Response Relationship or MDSE</i>
<b>Repurposed Molecular Entities</b>			
<b>Anto-SARS-CoV-2 Drugs</b>			
<i>Remdesivir (Gilead)</i>	None (Ebola dose) <sup>1</sup>	5 vs 10 days duration <sup>2</sup>	No
<b>Immunomodulators</b>			
<b>Anti-IL6</b>			
<i>Sarilumab (Sanofi)</i>	None, two dosing arms in randomized phase 3 trial <sup>3</sup>	N/A	No
<i>Tocilizumab (Genentech/Roche)</i>	None (CAR-T CRS dose) <sup>4</sup>	Adaptive dose-ranging phase 2, 4 dose levels <sup>5</sup> Confirmatory RCT ongoing <sup>6</sup>	No
<b>Anti-JAK/STAT</b>			
<i>Baricitinib (+ remdesivir) (Eli Lilly)</i>	None (EMA dose) <sup>7</sup>	Phase 1/2, including 4mg and 2mg <sup>8</sup>	No
<b>Corticosteroids</b>			
<i>Dexamethasone (Various)</i>	None (Sepsis/ARDS dose) <sup>9</sup>	10mg daily (experimental) vs 6mg daily (authorized dose) ongoing <sup>10</sup>	No
<i>Hydrocortisone (Various)</i>	None (Sepsis/ARDS dose) <sup>11</sup>	None	No
<b>New Molecular Entities</b>			
<b>Vaccine</b>			
<i>mRNA-1273 (Moderna)</i>	Non-human primate (2 dose levels) <sup>12</sup>	Surrogate endpoint-based, 50ug vs 100ug <sup>13</sup> Simulation-based study of lower doses <sup>16</sup>	No
<i>BNT162b2 (Pfizer/BioNTech)</i>	Randomized, phase 1/2, 5 dose levels <sup>14,15</sup>	Heterologous combo (BNT162b2, ChAdOx1 nCov-19)	No
<i>Ad26.COV2.S (Janssen)</i>	Randomized phase 1/2, 2 dose levels <sup>17</sup>	No	No
<i>ChAdOx1 nCov-19 (AstraZeneca-Oxford)</i>	Randomized phase 1/2, 2 dose cohorts (single vs two doses, all same dose) <sup>18</sup>	Heterologous combination (BNT162b2 & ChAdOx1 nCov- 19)	No
<b>Anti-SARS-CoV-2 Drugs</b>			
<i>Bamlanivimab</i>	Randomized phase 1/2/3, 3 dose levels (bamlanivimab) <sup>19</sup>		No
<i>Etesevimab (Eli Lilly)</i>	Randomized phase 1/2/3, 2 dose levels (etesevimab) <sup>19</sup>	No	No
<i>Casirivimab Imdevimab (Regeneron)</i>	Randomized phase 1/2/3, 2 dose levels (combination) <sup>20</sup>	No	No
<i>Sotrovimab (GlaxoSmithKline)</i>	Industry-sponsored randomized Phase 1/2/3 (no dose range) <sup>21</sup>	No	No

Table 1.

## References

- 1 Consultants, W. A. h. E. Deliberations on design options for randomized controlled clinical trials to assess the safety and efficacy of investigational therapeutics for the treatment of patients with Ebola virus disease. (Geneva, Switzerland, 2018).
- 2 Goldman, J. D. *et al.* Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med*, doi:10.1056/NEJMoa2015301 (2020).
- 3 Lescure, F. X. *et al.* Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* **9**, 522-532, doi:10.1016/S2213-2600(21)00099-0 (2021).
- 4 America, F. a. D. A. o. t. U. S. o. (ed Center for Drug Evaluation and Research) (Food and Drug Administration of the United States of America, 2017).
- 5 Strohbehn, G. W. *et al.* COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia. *Clin Pharmacol Ther*, doi:10.1002/cpt.2117 (2020).
- 6 ClinicalTrials.gov. *Low-dose Tocilizumab versus Standard of Care in Hospitalized Patients with COVID-19 (COVIDOSE-2)*, <<https://clinicaltrials.gov/ct2/show/NCT04479358>> (2020).
- 7 Agency, E. M. Olumiant, INN-baricitinib. (Amsterdam, The Netherlands, 2017).
- 8 Moreno-González, G. *et al.* A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. *Trials* **22**, 116, doi:10.1186/s13063-021-05072-4 (2021).
- 9 Villar, J. *et al.* Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med* **8**, 267-276, doi:10.1016/S2213-2600(19)30417-5 (2020).
- 10 *Higher vs Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia (COVIDSTEROID2)*, <<https://clinicaltrials.gov/ct2/show/NCT04509973>> (2020).
- 11 Tongyoo, S. *et al.* Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. *Crit Care* **20**, 329, doi:10.1186/s13054-016-1511-2 (2016).
- 12 Corbett, K. S. *et al.* Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *N Engl J Med* **383**, 1544-1555, doi:10.1056/NEJMoa2024671 (2020).
- 13 Chu, L. *et al.* A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine*, doi:<https://doi.org/10.1016/j.vaccine.2021.02.007> (2021).
- 14 Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and T. *Nature* **586**, 594-599, doi:10.1038/s41586-020-2814-7 (2020).
- 15 Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med* **383**, 2439-2450, doi:10.1056/NEJMoa2027906 (2020).
- 16 Jurgens, G. (medRxiv, 2021).
- 17 Sadoff, J. *et al.* Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *N Engl J Med* **384**, 1824-1835, doi:10.1056/NEJMoa2034201 (2021).
- 18 Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* **396**, 467-478, doi:10.1016/S0140-6736(20)31604-4 (2020).
- 19 States, F. a. D. A. o. t. U. Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. (Food and Drug Administration of the United States of America, Silver Springs, MD, USA, 2021).

- 1  
2  
3 20 States, F. a. D. A. o. t. U. (ed Food and Drug Administration of the United States) (Silver  
4 Springs, MD, USA, 2021).  
5 21 States, F. a. D. A. o. t. U. (ed Food and Drug Administration of the United States) (Silver  
6 Springs, MD, USA, 2021).  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# BMJ Open

## Dose Optimization and Scarce Resource Allocation: Two Sides of the Same Coin

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-063436.R2
Article Type:	Communication
Date Submitted by the Author:	08-Sep-2022
Complete List of Authors:	Strohbehn, Garth; VA Center for Clinical Management Research, Persad, Govind; University of Denver, Parker, William; University of Chicago Department of Medicine Murthy, Srinivas; University of British Columbia, Paediatrics
<b>Primary Subject Heading</b>:	Global health
Secondary Subject Heading:	Ethics, Health services research, Infectious diseases, Pharmacology and therapeutics, Public health
Keywords:	CLINICAL PHARMACOLOGY, Clinical trials < THERAPEUTICS, MEDICAL ETHICS, COVID-19, Public health < INFECTIOUS DISEASES, Rationing < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



## Dose Optimization and Scarce Resource Allocation: Two Sides of the Same Coin

Garth W Strohbehn, MD, MPhil<sup>1,2</sup>

Govind Persad, JD, PhD<sup>3</sup>

William F Parker, MD, PhD<sup>4,5</sup>

Srinivas Murthy, MDCM, MHSc<sup>6</sup>

<sup>1</sup>Veterans Affairs Ann Arbor Medical Center, Center for Clinical Management Research and <sup>2</sup>Rogel Comprehensive Cancer Center, University of Michigan Medicine, both in Ann Arbor, MI, USA; <sup>3</sup>University of Denver, Sturm College of Law, Denver, CO, USA; <sup>4</sup>Section of Pulmonary and Critical Care Medicine and <sup>5</sup>Maclean Center for Medical Ethics, University of Chicago, Chicago, IL, USA; and <sup>6</sup>Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada

**Journal:** *BMJ Open*

**Article Type:** Communication

**Article ID:** bmjopen-2022-063436.R2

**Previous BMJ Manuscript ID:** bmj-2021-067208

**Correspondence to:**

Garth W Strohbehn, MD, MPhil

Veterans Affairs Center for Clinical Management and Research

North Campus Research Center, B16-322W

Ann Arbor, MI 48105 USA

Email: gstrohbe@umich.edu

**Word count:** 4,050

**References:** 65

## 1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28           29           30           31           32           33           34           35           36           37           38           39           40           41           42           43           44           45           46           47           48           49           50           51           52           53           54           55           56           57           58           59           60

### 1   **Key Messages**

- 2           ● Resource scarcity reflects gross mismatch between supply and demand; societies strive to  
3           allocate scarce resources allocated in a manner that reflects their values
- 4           ● With regard to drugs and vaccines, a deep understanding of the relationship between a scarce  
5           drug’s dose and clinical response is necessary to appropriately distribute a supply-constrained  
6           drug
- 7           ● Future pandemic clinical trials should obtain dose optimization data in order to enable  
8           appropriate distribution

### 10   **Declarations**

11   **Ethics approval and consent to participate:** Not applicable

12   **Consent to publish:** Not applicable

13   **Availability of data and materials:** Not applicable

14   **Competing interests:** GWS is an employee of the US Government; the views expressed are his own and  
15   do not necessarily represent those of the Department of Veterans Affairs or US Government. GWS is a  
16   listed co-inventor of a filed patent held by the University of Chicago covering the use of low-dose  
17   tocilizumab in viral infections. GWS and SM have served in World Health Organization Clinical  
18   Therapeutics Working Groups; the views expressed are theirs and do not reflect the World Health  
19   Organization or other members of Working Groups.

20   **Funding:** This research received no specific grant from any funding agency in the public, commercial or  
21   not-for-profit sectors.

22   **Acknowledgments:** None.

### 25   **Contributors and sources**

26   GWS is a clinical trialist and health services researcher whose work centers on dose-optimization to  
27   combat drug scarcity and financial toxicity. He is a contributor to the World Health Organization’s Rapid  
28   Evidence Appraisal for COVID-19 Therapies. GP is a bioethicist and health law researcher. He has  
29   participated in a rapid expert consultation for the National Academies of Sciences, Engineering, and  
30   Medicine (USA) on COVID-19 therapeutic allocation. WFP is an intensivist and bioethicist whose work  
31   centers on scarce resource allocation. He chairs his institution’s COVID-19 Ethics Resource group. SM is  
32   an intensivist and infectious disease physician. He is a co-investigator of REMAP-CAP and is the co-chair  
33   of the WHO Clinical Characterization and Management research committee for COVID-19.

1  
2  
3 **1 Contributorship Statement**

4 2 GWS designed and conceptualized the work, interpreted findings, and drafted and revised the  
5 3 manuscript for intellectual content. GP, WFP, and SM interpreted findings, revised the manuscript, and  
6 4 provided intellectual content. The corresponding author attests that all listed authors meet authorship  
7 5 criteria and that no others meeting the criteria have been omitted. GWS is the guarantor.  
8 6

9  
10 **7 Patient involvement**

11 8 No patients were involved in the planning or conduct of this work.  
12 9  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 Abstract**  
4

5 2 Drug scarcity reflects gross mismatch between supply and demand. Under conditions of scarcity,  
6 3 societies strive to allocate scarce resources in a manner that best reflects their values, whatever they  
7 4 may be. Maximizing benefits and reducing inequities are two major values that guide allocation  
8 5 decisions. A deep understanding of the relationship between a scarce drug's dose and clinical response  
9 6 is necessary to appropriately distribute a supply-constrained drug along these lines. The vast majority of  
10 7 drug development and repurposing during the COVID-19 pandemic – an event that has made clear the  
11 8 ever-present scarcity in healthcare systems – has been ignorant of scarcity and dose optimization's  
12 9 ability to help address it. Future pandemic clinical trials systems should obtain dose optimization data,  
13 10 as these appear necessary to enable appropriate scarce resource allocation according to societal values.  
14 11

15 12 **Keywords:** global health, public health, medical ethics, clinical trials  
16 13  
17 14  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 Background

2 Absolute scarcity – when demand for a resource vastly exceeds a limited supply – has been a recurring  
3 theme of the COVID-19 pandemic.<sup>1</sup> Under absolute scarcity, resource allocation is inevitably zero sum.  
4 Increasing supply of an absolutely scarce resource through increased production is one approach, but  
5 for certain resources, this may not be feasible (scientifically or politically) over the timescale required to  
6 nimbly and effectively respond to scarcity.<sup>2</sup> Societies must then confront the tragic dilemmas scarcity  
7 imposes by allocating absolutely scarce resources in a manner that reflects their values, whatever those  
8 values may be.<sup>2,3</sup> In a strained health environment, many countries will seek to allocate scarce medical  
9 interventions to balance benefit maximization with inequity minimization. Doing so requires first  
10 knowing how much of the absolutely scarce resource is available, and second, knowing how much  
11 benefit recipients of the resource can expect to gain from each additional unit they receive. This second,  
12 key piece of information requires an understanding of the relationship between the scarce resource's  
13 dose and clinical efficacy.<sup>4</sup>

14 A resource's ability to benefit individuals and populations depends on its abundance or scarcity.  
15 For resources that are *not* abundant, tradeoffs between the relative welfares of individuals and  
16 populations become inevitable.<sup>2</sup> These tradeoffs become especially acute when considering the  
17 absolute scarcity of medical resources during a pandemic.

18 The conventional drug development paradigm is oriented toward the individual. It assumes that  
19 the drug is abundant with respect to the potential recipient, with neither limits on access nor tradeoffs  
20 between different recipients. Critically, for the individual who is eligible to receive a given candidate  
21 therapy in the context of a clinical trial, that therapy is itself abundant because the dosing regimen does  
22 not impact other potential recipients' access. Drug development thus occurs under a critical assumption:  
23 Maximizing the benefit that each individual recipient gleans from a drug will necessarily maximize total  
24 population benefits. Dose-finding and efficacy studies therefore strive to maximize the net benefit for  
25 each individual recipient of the candidate therapy. In the context of an early phase clinical trial of an  
26 abundant drug, administering more than the minimum amount needed to achieve maximum benefit  
27 presents no issue, so long as the additional amount does not increase harms.

28 The abundance assumption implied by conventional drug development falters under scarcity.  
29 Drug resources, including those that appear abundant before a disaster strikes,<sup>5,6</sup> can quickly become  
30 absolutely scarce. When absolute scarcity and its attendant tradeoffs emerge, administration of  
31 excessive amounts of drug to some individuals, by excluding other potential recipients from *any* benefit,  
32 *reduces* the total population benefits that could have been gleaned. Further, this form of overdosing

1 exacerbates inequities between those with access and those without.<sup>7</sup> In truth, an infinite number of  
2 dose levels are theoretically possible for a given drug. For physicians and policymakers navigating  
3 scarcity dosing of an absolutely scarce resource is an optimizable choice – but it requires re-approaching  
4 dosing with consideration of both scarcity and public health.

5

## 6 **Main Text**

7

### 8 *Selected Dose Levels in COVID-19*

9 On the basis of demonstrated clinical benefit, 13 drugs (including vaccines) have been approved or  
10 authorized by high-income governments for the treatment or prevention of COVID-19 as of October 1,  
11 2021, with many more in development or subsequently approved.<sup>8</sup> Dosing uncertainty persists for each  
12 of these drugs (**Table 1**), in turn reducing health system capacity, efficiency of supply utilization, and  
13 population health. To better understand the specific dose level that we ought to target in pandemic  
14 drug development, however, it is useful to review the dose levels that have been chosen thus far.

15

### 16 *Labeled Dose for Prior Indication*

17 The dosages of drugs repurposed for treatment of COVID-19 have almost uniformly duplicated those in  
18 the drug's original, pre-COVID-19 indication (**Table 1**). Prior clinical information provides investigators  
19 with the pharmacokinetic and safety information needed to rapidly incorporate a candidate drug into a  
20 clinical trial evaluating efficacy, bypassing traditional early-phase dose-finding research.<sup>9</sup> If the dose  
21 used for the original indication *exceeds* the minimum dose needed to demonstrate efficacy in COVID-19,  
22 then investigators are able to determine whether the drug is in fact an efficacious therapy for COVID-19.  
23 The speed conferred by bypassing front-end dose-finding benefits patients through earlier identification  
24 of efficacious drugs. But this strategy, by not attempting to identify an optimal dose for the drug specific  
25 for COVID-19 introduces two major risks: First, that, because of relative *underdosing*, a clinical trial may  
26 reach a false negative conclusion about the drug's efficacy and second, that the appropriate dose for the  
27 original indication is in truth excessive for COVID-19, exacerbating scarcity and potentially resulting in  
28 excess harms (neither of which are knowable at trial initiation). While there are clear efficiencies to be  
29 gained by building on prior knowledge of the drug's performance for its original indication, the absences  
30 of both individual- and population-level dose optimization may exhaust drug supplies or harm individual  
31 recipients at rates far higher than necessary.

<i>Drug (Manufacturer)</i>	<i>Dedicated COVID-19 Dose-Finding Study</i>	<i>Post-RCT Dose Optimization or Supply Expansion Clinical Trial</i>	<i>Defined Dose- Response Relationship or MDSE</i>
<b>Repurposed Molecular Entities</b>			
<b>Anto-SARS-CoV-2 Drugs</b>			
<i>Remdesivir (Gilead)</i>	None (Ebola dose) <sup>10</sup>	5 vs 10 days duration <sup>11</sup>	No
<b>Immunomodulators</b>			
<b>Anti-IL6</b>			
<i>Sarilumab (Sanofi)</i>	None, two dosing arms in randomized phase 3 trial <sup>12</sup>	N/A	No
<i>Tocilizumab (Genentech/Roche)</i>	None (CAR-T CRS dose) <sup>13</sup>	Adaptive dose-ranging phase 2, 4 dose levels <sup>14</sup> Confirmatory RCT ongoing <sup>15</sup>	No
<b>Anti-JAK/STAT</b>			
<i>Baricitinib (+ remdesivir) (Eli Lilly)</i>	None (EMA dose) <sup>16</sup>	Phase 1/2, including 4mg and 2mg <sup>17</sup>	No
<b>Corticosteroids</b>			
<i>Dexamethasone (Various)</i>	None (Sepsis/ARDS dose) <sup>18</sup>	10mg daily (experimental) vs 6mg daily (authorized dose) ongoing <sup>19</sup>	No
<i>Hydrocortisone (Various)</i>	None (Sepsis/ARDS dose) <sup>20</sup>	None	No
<b>New Molecular Entities</b>			
<b>Vaccine</b>			
<i>mRNA-1273 (Elasomeran [INN]) (Moderna)</i>	Non-human primate (2 dose levels) <sup>21</sup>	Surrogate endpoint-based, 50ug vs 100ug <sup>22</sup> Simulation-based study of lower doses <sup>25</sup>	No
<i>BNT162b2 (Tozinameran [INN]) (Pfizer/BioNTech)</i>	Randomized, phase 1/2, 5 dose levels <sup>23</sup> <sub>24</sub>	Heterologous combo (BNT162b2, ChAdOx1 nCov-19)	No
<i>Ad26.COV2.S (Janssen)</i>	Randomized phase 1/2, 2 dose levels <sup>26</sup>	No	No
<i>ChAdOx1 nCov-19 (AstraZeneca-Oxford)</i>	Randomized phase 1/2, 2 dose cohorts (single vs two doses, all same dose) <sup>27</sup>	Heterologous combination (BNT162b2 & ChAdOx1 nCov- 19)	No
<b>Anti-SARS-CoV-2 Drugs</b>			
<i>Bamlanivimab Etesevimab (Eli Lilly)</i>	Randomized phase 1/2/3, 3 dose levels (bamlanivimab) <sup>28</sup> Randomized phase 1/2/3, 2 dose levels (etesevimab) <sup>28</sup>	No	No
<i>Casirivimab Imdevimab (Regeneron)</i>	Randomized phase 1/2/3, 2 dose levels (combination) <sup>29</sup>	No	No
<i>Sotrovimab (GlaxoSmithKline)</i>	Industry-sponsored randomized Phase 1/2/3 (no dose range) <sup>30</sup>	No	No

**Table 1. Dose optimization of repurposed and new molecular entities for SARS-CoV-2 and COVID-19 as of Summer 2021.** Drugs that have received regulatory approval or authorization, as well as U.S. guideline-recommended drugs, for the prevention or treatment of COVID-19 are summarized in the table. From left to right, columns demonstrate minimal pre-RCT dose-finding in COVID-19, a limited number of welfare-maximizing dose optimization trials, and the absence of any MDSE identification in COVID-19 therapeutics. **Abbreviations:** RCT, randomized, controlled trial; MDSE, minimum dose with satisfactory efficacy; IL-6, interleukin-6; CAR-T CRS, chimeric antigen T-cell receptor-related cytokine release syndrome; EMA, European Medicines Agency; JAK, Janus kinase; STAT, signal transducer and activator of transcription proteins; ARDS, acute respiratory distress syndrome.

### Model-Informed Drug Repurposing

1  
2  
3 1 Model-informed drug repurposing (MIDR) uses *in vitro* estimates of a repurposed drug's activity against  
4 a novel pathogen, such as COVID-19, to guide initial anti-infective dosing. As a pathogen becomes better  
5 characterized during the course of a pandemic, investigators can connect pharmacokinetics to  
6 epidemiologic modeling, enabling clinical trials to administer the (presumed) right dose of therapy at the  
7 right time, enhancing the odds of demonstrating efficacy if it truly exists.<sup>31</sup> Importantly, however, the  
8 small molecule antiviral drugs for which MIDR has been employed have not been shown to reduce  
9 COVID-19-related mortality.<sup>32</sup> Instead, in the COVID-19 pandemic, the pathogen-directed approaches  
10 demonstrated to reduce mortality have uniformly been new chemical entities.<sup>33 34</sup> Coupled with MIDR's  
11 requirement for an *in vitro* assay to be developed and validated to guide dosing decisions, the benefits  
12 of host-targeted therapies,<sup>35</sup> and the speeds with which novel antibody-based antiviral and mRNA  
13 vaccine development can occur, MIDR may be ill-suited to both rapid and accurate action in future viral  
14 pandemics.

#### 15 *Dosing Informed by Randomized, Dose-Ranging Trials*

16 Randomized, placebo-controlled dose-ranging studies directly compare multiple dose levels (including  
17 placebo) to one another to identify signs of clinical activity and the extent to which a dose-response  
18 relationship exists. These trials are often conducted in phase 2, *before* confirmatory efficacy trials that  
19 use gold-standard clinical endpoints. Timing is critical: Randomized, placebo-controlled dose-ranging  
20 studies evaluating key surrogate clinical endpoints can enable dosing that responds to emergency  
21 conditions. For example, the BLAZE-1 trial evaluated whether any of three different doses (700mg,  
22 2800mg, 7000mg) of bamlanivimab reduced SARS-CoV-2 viral load.<sup>36</sup> Despite only the 2800mg arm  
23 reducing SARS-CoV-2 viral load, the 700mg dose was granted Emergency Use Authorization (EUA) by the  
24 U.S. Food and Drug Administration due to its comparable reduction in emergency care utilization and  
25 hospitalization – instantaneously providing a many-fold increase in the number of patients who could  
26 benefit from what would be a very limited initial supply of drug. BLAZE-1 was not powered to make a  
27 determination of small differences in these important outcomes between different dose levels. Despite  
28 this limitation, though, a decision that prioritized population health over individual health was made.

29 More disappointing for global health advocates, however, has been an absence of urgency in  
30 pursuing SARS-CoV-2 vaccine dose optimization. For example, half-dose (50µg) mRNA-1273 generates  
31 SARS-CoV-2-neutralizing antibodies and seroconversion at rates nearly equivalent to full dose, with all  
32 half-dose recipients in the trial seroconverting by six weeks after the first dose.<sup>22</sup> Similar findings have  
33 been suggested for the BNT162b2 mRNA vaccine.<sup>25</sup> Similarly, quarter-dose (25µg) mRNA-1273 is



1  
2  
3 1 sufficient to generate durable cellular immunity against SARS-CoV-2.<sup>37</sup> As it relates to boosters, dose-  
4  
5 2 finding studies might even allow for a massive reduction in vaccine supply utilization while minimizing  
6  
7 3 risk of adverse events.<sup>38</sup> Yet this concept has not been pursued in follow-up trials, despite the potential  
8  
9 4 to instantaneously increase access at least 2-4 fold while simultaneously reducing the likelihood of  
10  
11 5 adverse events, especially in the adolescent and young adult subpopulations at risk for vaccine-related  
12  
13 6 myocarditis.

13 7 Administering drug at a lower dose, known as fractional dosing, rations divisible scarce  
14  
15 8 resources to increase the number of recipients who have the potential to benefit from a relatively fixed  
16  
17 9 supply of scarce resource. The approach acknowledges that individuals who receive a lower dose could  
18  
19 10 be “worse off” than if they had access to and received the full dose. However, the social value gained by  
20  
21 11 multiplying the number of recipients by two-fold (or more) more than compensates for the potentially  
22  
23 12 reduced efficacy each recipient experiences. In the COVID-19 pandemic, for example, meaningful  
24  
25 13 reductions in both infections and deaths would likely have occurred had a half-dose mRNA vaccine  
26  
27 14 achieved an efficacy 70% that of the full-dose mRNA vaccine.<sup>39</sup> In light of the evidence cited above  
28  
29 15 showing the near-equivalence of low-dose mRNA vaccines<sup>22 25 37</sup> as well as the possibility that the  
30  
31 16 emergence of SARS-CoV-2 variants would have been *reduced* by using a fractional dosing strategy  
32  
33 17 focused on vaccinating as many individuals as possible, as quickly as possible,<sup>40</sup> it is plausible that the  
34  
35 18 failure to optimize doses and enact fractional dosing led not only to unnecessary morbidity and  
36  
37 19 mortality but also a lengthening of the COVID-19 pandemic.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 1 Potential Dose Levels for Future Pandemic Drug Development

2 The extent to which a pandemic drug's dose is ideal depends on the lens through which one views the  
3 allocation problem. Optimizing dose to population health instead of individual health often leads to very  
4 different dosing decisions. Two approaches to dosing are described below.

#### 5 6 *Minimum Dose with Satisfactory Efficacy*

7 The minimum dose with satisfactory efficacy (MDSE) approach pre-defines a satisfactory level of efficacy  
8 and then identifies the minimum amount of drug needed to achieve that level, based on the dose-  
9 response information provided by dose-ranging studies.<sup>41</sup> The MDSE approach is best suited for a clinical  
10 context in which a drug is *known* to have efficacy when administered at a given dose, frequency, route  
11 of administration, and duration. Ideally, the MDSE would be identified in clinical trials; the presence of  
12 at least one cohort of patients that receives a dose level(s) that is less than the MDSE provides a  
13 measure of confidence that MDSE is, in fact, MDSE. Downsides to the MDSE-focused approach include  
14 the time needed to optimize the drug's dose after confirming its efficacy at the higher, non-MDSE dose  
15 and the suboptimal efficacy that would be experienced by any study arms that receive a dose lower  
16 than MDSE in a clinical trial. Low-dose tocilizumab<sup>14</sup> and pre-clinical attempts toward mRNA vaccine  
17 dose minimization are examples of attempted MDSE identification during the COVID-19 pandemic.<sup>22 37</sup>  
18 MDSE-based drug development operates from a socially-minded yet individual-dominant perspective,  
19 wherein the arrived upon MDSE depends upon a society's definition of "satisfactory".

#### 20 21 *Socially Optimal Dose*

22 The socially optimal dose (SOD) is still more socially-minded. SOD is the theoretical dose at which  
23 individual efficacy-per-unit is maximized (**Figure 1**). Utilization of the SOD sacrifices maximal efficacy for  
24 each recipient in order to increase population-level benefit by increasing the number of recipients.<sup>4</sup> The  
25 SOD, derived from estimates of the population-level dose-response relationship, attempts to maximize  
26 the quantity of benefit the drug produces without regard to distribution, and may facilitate allocation  
27 strategies that focus solely on maximizing population-level efficacy. One real-world example of (more)  
28 socially optimal dosing – outside the bounds of a clinical trial – was the use of extended-interval dosing  
29 of mRNA vaccines, in which the potential risk of worsened individual-level outcomes due to the  
30 extended dose interval was accepted in exchange for the potential benefit of protecting more people,  
31 acknowledging recipients may receive sub-optimal protection by straying from the evidence base.<sup>39 42</sup> In

1  
2  
3 1 retrospect, although this was a successful calculated risk, testing the strategy prospectively through  
4 2 clinical trials would have been preferred.<sup>43-45</sup>

#### 6 3 8 4 *Mathematical Models' Guidance*

9 5 Epidemiologic models of viral pandemics, in combination with economic models describing  
10 6 implementation of mitigation and vaccination, enable side-by-side comparison of resource allocation  
11 7 strategies against a range of counterfactuals and under a range of assumptions.<sup>39 40 46-48</sup> Conditioned on  
12 8 a given drug or vaccine having been shown to be efficacious, the most relevant question for public  
13 9 health becomes how to, in an efficient and accurate manner, maximize the population benefits that can  
14 10 be derived from a scarce supply of that resource. Determining what “socially optimal” may be in the  
15 11 rapidly evolving evidence space of a global pandemic is inherently challenging and depends upon  
16 12 multiple, imperfectly known factors, including: vaccine effectiveness, *relative* effectiveness of lower  
17 13 doses, the maximum rate with which vaccination efforts proceed, and characteristics of the pandemic  
18 14 itself (e.g., incubation period, rates of spread and replication, and mortality). Prior outbreaks, including  
19 15 influenza,<sup>49</sup> cholera,<sup>50</sup> and yellow fever, demonstrate the value of taking a rational approach to scarce  
20 16 vaccine allocation guided by mathematical models. Such efforts came about, however, once scarcity had  
21 17 arrived, rather than pre-emptively, *during* drug and vaccine development.

#### 22 18 23 19 24 20 *Strategic Pandemic Clinical Trial Systems for the Future*

25 21 Under the relative abundance present outside a pandemic, once an efficacious therapy is identified,  
26 22 clinical trialists most commonly turn their attention to the *next* candidate drug – for example, by asking  
27 23 “*Can addition of a new therapy improve a given individual’s outcome?*” However, from a population  
28 24 health perspective, the key question often is “*How do we, as a health system, maximize the benefits*  
29 25 *generated by this therapy’s finite supply?*”

30 26 During a pandemic, conscientious policymakers will often adopt strategies that allocate scarce  
31 27 resources according to societal values, including toward maximization of benefit and reduction of  
32 28 inequities.<sup>3</sup> Simulations of vaccine allocation in which lives saved is the primary outcome,<sup>25</sup> as well as  
33 29 real-world evidence,<sup>43 44</sup> demonstrate the necessity of knowing in real-time the dose-efficacy  
34 30 relationship and an approach that aligns with allocation of scarce resource based on SOD. Either MDSE-  
35 31 or SOD-based allocation schemas would be well-suited to navigating pandemic-fueled drug scarcity in  
36 32 order to improve population health, but their derivation may require dose-ranging clinical trials. How,

1  
2  
3 1 then, to incorporate dose-optimization studies and enable welfare maximization more efficiently in the  
4  
5 2 future?

6  
7 3 Incorporation of dose-optimization studies into platform trials is a next step toward maximizing  
8  
9 4 population health, and the answer likely resides in blended trials that combine efficacy assessment with  
10  
11 5 dose-optimization. Employed at scale, platform trials have allowed for rapid identification of efficacious  
12  
13 6 repurposed therapies through simultaneous evaluation of multiple candidate drugs.<sup>9</sup> Therefore, a two-  
14  
15 7 step approach in which efficacy is first determined in a platform trial, followed immediately by  
16  
17 8 randomized, dose-ranging studies aimed at dose optimization (perhaps guided by surrogate endpoints  
18  
19 9 derived from the earlier, larger definitive RCTs, such as correlates of protection<sup>51 52</sup>) can provide  
20  
21 10 physicians and policymakers with the information needed to best allocate scarce resources toward  
22  
23 11 population health aims. Seamless clinical trial designs proceeding from dose-finding to efficacy  
24  
25 12 assessment have previously been conducted.<sup>53 54</sup> Given the need to rapidly begin generating benefits, a  
26  
27 13 future pandemic research paradigm should begin first with an assessment of a drug's potential to  
28  
29 14 generate benefits for an individual patient, followed by a thorough exploration of the dose-efficacy  
30  
31 15 relationship to inform optimal allocation.

### 32 17 *Optimizable Components of Dose*

33 18 Once a given drug's efficacy has been established, optimization research is needed to understand the  
34  
35 19 patient- and drug-related factors most responsible for the drug's success. A drug's efficacy depends  
36  
37 20 upon the extent to which its target is exposed to the drug (i.e., the exposure). Exposure itself is a  
38  
39 21 function of dose, which can be framed as the discrete quantum of drug administered (whether it be a  
40  
41 22 flat dose for all subjects or a personalized, weight-based dose), the frequency with which that quantum  
42  
43 23 is administered (e.g., once vs recurring), the time duration over which a patient is exposed to the drug,  
44  
45 24 and the route of administration. Lowering the quantum administered, reducing the frequency and  
46  
47 25 duration of administration, and altering the route of administration can all help reduce the total amount  
48  
49 26 of drug used while, simultaneously, achieving sufficient exposure.

50  
51 27 As discussed in preceding sections, this question is orthogonal to, but no less important than,  
52  
53 28 the original efficacy question more commonly examined in conventional studies. Clinical trial methods  
54  
55 29 that efficiently accomplish the task of dose optimization while 1) adhering to core ethical constraints  
56  
57 30 (namely the absence of a placebo arm once a given drug's efficacy has been established) and 2)  
58  
59 31 recruiting efficiently are at this time being elucidated. Dose optimization *after* confirmation of a drug's  
60  
32 efficacy is, essentially, a one-way sensitivity analyses: That is, they would evaluate the impact of lower

1  
2  
3 1 quanta, less frequent administration, shorter duration, and/or different routes on efficacy. These  
4  
5 2 designs may come to resemble DURATIONS designs previously developed to efficiently examine  
6  
7 3 antibiotic regimen durations.<sup>55 56</sup> Clever use of Bayesian prospective clinical trials in sequence may  
8  
9 4 unlock new efficiencies.  
10  
11 5

### 12 6 Considerations for Trialists, Health Systems, and Policymakers

13 7 Incorporation of dose optimization of scarce medical resources is not without its challenges or criticisms.  
14  
15 8 First, clinicians, researchers, and participants must be convinced that the risk to an individual involved in  
16  
17 9 a dose-optimization trial is reasonable, when viewed in relation to the social value that the trial  
18  
19 10 provides. Individuals enrolled in dose-optimization studies ultimately bear the risks of these trials. Chief  
20  
21 11 among these is the risk that the lower dose has lower efficacy than the previously tested dose, a risk  
22  
23 12 that can be mitigated by allowing for crossover. Counterintuitive *benefits* may emerge: Lower doses may  
24  
25 13 have improved safety profiles and individuals enrolling in dose-optimization trials may receive access to  
26  
27 14 therapies earlier than those who do not. Individuals enrolled in dose-optimization trials may therefore,  
28  
29 15 on balance, *benefit* from the lower dose – while also contributing to potentially substantial population  
30  
31 16 benefit. While the populations to which MDSE and SOD will apply are more heterogeneous than the  
32  
33 17 population in which a dose-ranging clinical trial is conducted, a dose-ranging study would be a  
34  
35 18 potentially high-reward incremental step.

36  
37 19 Second, critics may worry that dose optimization will lengthen development, repurposing, and  
38  
39 20 authorization or approval timelines, or unnecessarily *increase* the rate at which stockpiles of absolutely  
40  
41 21 scarce drugs are used. Dose optimization indeed requires time, but simulation and real-world studies  
42  
43 22 suggest it can enable implementation strategies that save more lives.<sup>4 25 43-45</sup> Two-staged result reporting  
44  
45 23 – efficacy trial result first, followed by dose optimization – may allow patients to benefit from a therapy  
46  
47 24 with demonstrated efficacy while dose optimization efforts are ongoing. Unpredictable supply chains  
48  
49 25 and increased demand leave clinicians and patients to grapple with a fundamental question “Is it worth  
50  
51 26 the risk *to this patient*, who has access to the scarce medicine, to potentially provision a lower dose?”  
52  
53 27 Within the individual doctor-patient relationship, public health arguments lack an advocate, resulting in  
54  
55 28 an answer of “No.” Health authorities and regulators must make efforts to ensure adequate drug supply  
56  
57 29 for dose optimization clinical trials, and hospital authorities should cordon off supplies for dose  
58  
59 30 optimization trials that may serve the greater good.

60  
61 31 Third, the successes of corticosteroids for hospitalized patients with COVID-19 who require  
62  
63 32 supplemental oxygen might suggest avoiding the need for dose optimization by limiting our efforts to

1  
2  
3 1 abundant therapies. This line of thinking represents supply-consciousness but has strategic flaws: It  
4 2 limits the universe of potential therapies that can be tested, no matter how well-reasoned  
5 3 mechanistically; fails to anticipate that a therapy being studied could become scarce in the future; and  
6 4 neglects geographic heterogeneity in abundance/scarcity. Extending the supplies of relatively abundant  
7 5 drugs *in the event of higher than anticipated demand* is consistent with a benefit-maximizing, inequity-  
8 6 minimizing strategy. Moreover, failing to reconsider the dose of abundant drugs risks *under-dosing* and  
9 7 failure to capture population benefits that otherwise could have been achieved.

10 8 Some may contend that lower doses should not be used until clinical efficacy is established in a  
11 9 confirmatory clinical trial comparing low-dose to standard-dose, implying that development timelines  
12 10 will be lengthened. While of course a reasonable concern, risk calculus is contextual. Whether to adopt a  
13 11 lower dose of an absolutely scarce therapy based on suboptimal evidence must be decided in awareness  
14 12 of the dangers resulting from ongoing absolute scarcity. Expanding population access to a therapy by  
15 13 lowering the dose – even if doing so sacrifices some degree of individual-level efficacy – may be socially  
16 14 optimal, ethical, and in line with the goals of a given society.<sup>4,57</sup> Generation of this information alone  
17 15 does not compel policymakers to action.

18 16 Last, some may worry that dosing strategies that aim to promote population health treat  
19 17 *individual* recipients inequitably, by providing a dose that is less beneficial than the dose that would be  
20 18 provided under abundance. But, under scarcity, maintaining the dosing strategies used under  
21 19 abundance may exclude many who can benefit. Maximizing benefits for a few recipients while leaving  
22 20 many unprotected for want of access is likely to neither maximize population welfare nor serve a  
23 21 society's equity goals. Indeed, a dose-optimized approach to scarce medicines may facilitate fulfillment  
24 22 of rational pharmacotherapy's goal of ensuring therapeutically sound and cost-effective use of  
25 23 medicines in a post-COVID-19 world.

### 24 25 **Applying Scarcity-Oriented Development to the Next Pandemic**

26 26 Many of these same themes and debates have re-emerged in the past 6 months. Since this manuscript  
27 27 was initially submitted, monkeypox has been declared a public health emergency of international  
28 28 concern.<sup>58</sup> Authorities in the U.S. appear keen to avoid the accessibility issues that plagued the COVID-  
29 29 19 vaccine rollout. In addition to adopting a "first doses first" strategy in some localities,<sup>59</sup> federal-level  
30 30 policymakers will allow federal drug regulators to provide EUA for fractional dosing of monkeypox  
31 31 vaccine (modified vaccinia Ankara [MVA]),<sup>60</sup> drawing on a previously conducted randomized, controlled  
32 32 trial comparing full-dose subcutaneous injection of two different forms of MVA with one-fifth dose

1 intradermally.<sup>61</sup> Notably in the trial, recipients received two doses of MVA.<sup>61</sup> Alongside this extrapolation  
2 and concern that intradermal injection will be suboptimal when implemented in the real world,  
3 adoption of fractional dosing has been criticized.<sup>62</sup>

4 Recognizing the evidentiary ambiguity, clinical trialists are starting to ask the right, public health-  
5 oriented questions. The U.S.-based National Institute of Allergy and Infectious Diseases is sponsoring a  
6 prospective, randomized, controlled phase 2 trial evaluating two doses of one-fifth dose MVA  
7 (intradermal), two doses of one-tenth dose MVA (intradermal) against two doses of a full-dose standard  
8 of care (delivered subcutaneously).<sup>63 64</sup> There is, however, cause for great concern in the execution of  
9 this research vision. The proposed trial,<sup>64</sup> which is not yet recruiting, employs a non-inferiority  
10 hypothesis structure in evaluating peak antibody in patients 18 to 50 years of age. Of note, the initial  
11 trial plan does not include a *clinical* efficacy endpoint. Together, these factors raise the worrying  
12 possibility that this much-needed dose optimization trial could, despite not having defined the minimal  
13 antibody response needed to confer protection, reject the fractional dosing strategy on the basis of  
14 inferior peak antibody responses alone and, simultaneously, fail to identify *clinical* near-equivalence  
15 between the three tested dose levels if it does exist. The BLAZE-1 trial may be informative: Even  
16 underpowered clinical outcomes can influence decision-making. Moreover, the COVID-19 experience  
17 suggests that even a positive trial that demonstrates the non-inferiority of fractional dosing's antibody  
18 response would fail to convince skeptical public health authorities or regulators, due to the failures to  
19 provide either a clinical endpoint or meaningful data for patients over 50 years of age. The extent to  
20 which the science of fractional dosing will be furthered is limited by the trial's inability to independently  
21 correlate threshold antibody titers with clinical protection as well as its likely inability to identify both  
22 the MDSE and SOD. Finally, by virtue of the study's three-arm design, the potential vaccine supply  
23 expansion is inherently capped at a 10-fold increase, which may not be sufficient to protect all  
24 individuals in some locales.

## 25 26 27 **Conclusions**

28 Clinical care provided under conditions of scarcity and clinical care provided under conditions of  
29 abundance are profoundly different. Society's ability to maximize the benefits that could be generated  
30 from its scarce drug supplies was hampered by a lack of information and an inability or unwillingness to  
31 ask key questions. Research questions and the clinical trials used to answer them must acknowledge the  
32 stark differences between care under scarcity and care under abundance in order to serve population

1 health goals. Policymakers must make strategic decisions to navigate scarcity, and medicine's role is to  
2 provide policymakers with information that guides decision-making. Dosing remains a major inefficiency  
3 to be improved upon in pandemic preparedness. Indeed, in a post-COVID-19 future, these issues are  
4 likely to persist for high-cost cancer and rheumatology drugs in low- and middle-income countries,  
5 where the drugs may be available but the means to acquire them are scarce.<sup>57 65</sup> Clinical trial systems,  
6 supported by policy-makers, must acknowledge scarcity and take appropriate steps to optimize dosing.  
7 Though methodologic questions remain, a two-step model of innovation that recognizes and then  
8 balances the inherent tension between population health and individual health under scarcity is one  
9 potential approach moving forward.

10

11

12

13

#### 14 **List of Abbreviations**

15 **COVID-19:** Novel coronavirus disease 2019

16 **EUA:** Emergency Use Authorization

17 **MDSE:** Minimum dose with satisfactory efficacy

18 **MIDR:** Model-informed drug repurposing

19 **MRNA:** Messenger ribonucleic acid

20 **RCT:** Randomized, controlled trial

21 **SARS-CoV-2:** Severe acute respiratory syndrome coronavirus 2

22 **SOD:** Socially optimal dose



## 1 References

- 2 1. Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's  
3 Front Line. *N Engl J Med* 2020;382(20):1873-75. doi: 10.1056/NEJMp2005492 [published  
4 Online First: 2020/03/18]
- 5 2. Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical  
6 interventions. *Lancet* 2009;373(9661):423-31. doi: 10.1016/S0140-6736(09)60137-9
- 7 3. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time  
8 of Covid-19. *N Engl J Med* 2020 doi: 10.1056/NEJMs2005114 [published Online First:  
9 2020/03/23]
- 10 4. Strohbehn GW, Parker WF, Reid PD, et al. Socially optimal pandemic drug dosing. *The Lancet*  
11 *Global Health* 2021 doi: 10.1016/S2214-109X(21)00251-5
- 12 5. Águas R, Mahdi A, Shretta R, et al. Potential health and economic impacts of dexamethasone  
13 treatment for patients with COVID-19. *Nat Commun* 2021;12(1):915. doi:  
14 10.1038/s41467-021-21134-2 [published Online First: 2021/02/10]
- 15 6. Administration FaD. FDA Drug Shortages - Dexamethasone Sodium Phosphate Injection 2021  
16 [Available from:  
17 [https://www.accessdata.fda.gov/scripts/drugshortages/dsp\\_ActiveIngredientDetails.cfm?AI=Dexamethasone%20Sodium%20Phosphate%20Injection&st-ct&tab=tabs-1#](https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexamethasone%20Sodium%20Phosphate%20Injection&st-ct&tab=tabs-1#)  
18 accessed February 3 2021.
- 19 7. Kruk ME, Gage AD, Arsenault C, et al. High-quality health systems in the Sustainable  
20 Development Goals era: time for a revolution. *Lancet Glob Health* 2018;6(11):e1196-  
21 e252. doi: 10.1016/S2214-109X(18)30386-3 [published Online First: 2018/09/05]
- 22 8. Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. *Nat Rev Drug Discov* 2021  
23 doi: 10.1038/d41573-021-00037-3 [published Online First: 2021/02/25]
- 24 9. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple  
25 treatments. *JAMA* 2015;313(16):1619-20. doi: 10.1001/jama.2015.2316
- 26 10. Consultants WAhE. Deliberations on design options for randomized controlled clinical trials  
27 to assess the safety and efficacy of investigational therapeutics for the treatment of  
28 patients with Ebola virus disease. In: WHO, ed. WHO R&D Blueprint. Geneva,  
29 Switzerland, 2018.
- 30 11. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe  
31 Covid-19. *N Engl J Med* 2020 doi: 10.1056/NEJMoa2015301 [published Online First:  
32 2020/05/27]
- 33 12. Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with  
34 severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3  
35 trial. *Lancet Respir Med* 2021;9(5):522-32. doi: 10.1016/S2213-2600(21)00099-0  
36 [published Online First: 2021/03/04]
- 37 13. America FaDAotUSo. Multi-discipline review: Application number BLA 125276 S-114. In:  
38 Research CfDEa, ed.: Food and Drug Administration of the United States of America,  
39 2017.
- 40 14. Strohbehn GW, Heiss BL, Rouhani SJ, et al. COVIDOSE: A phase 2 clinical trial of low-dose  
41 tocilizumab in the treatment of non-critical COVID-19 pneumonia. *Clin Pharmacol Ther*  
42 2020 doi: 10.1002/cpt.2117 [published Online First: 2020/11/18]

15. ClinicalTrials.gov. Low-dose Tocilizumab versus Standard of Care in Hospitalized Patients with COVID-19 (COVIDOSE-2) Washington, D.C.: U.S. National Library of Medicine; 2020 [Available from: <https://clinicaltrials.gov/ct2/show/NCT04479358>].
16. Agency EM. Olumiant, INN-baricitinib. Amsterdam, The Netherlands, 2017.
17. Moreno-González G, Mussetti A, Albasanz-Puig A, et al. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. *Trials* 2021;22(1):116. doi: 10.1186/s13063-021-05072-4 [published Online First: 2021/02/05]
18. Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med* 2020;8(3):267-76. doi: 10.1016/S2213-2600(19)30417-5 [published Online First: 2020/02/07]
19. Higher vs Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia (COVIDSTEROID2) ClinicalTrials.gov2020 [Available from: <https://clinicaltrials.gov/ct2/show/NCT04509973> accessed June 20 2021.
20. Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. *Crit Care* 2016;20(1):329. doi: 10.1186/s13054-016-1511-2 [published Online First: 2016/10/15]
21. Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *N Engl J Med* 2020;383(16):1544-55. doi: 10.1056/NEJMoa2024671 [published Online First: 2020/07/28]
22. Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine* 2021 doi: <https://doi.org/10.1016/j.vaccine.2021.02.007>
23. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T. *Nature* 2020;586(7830):594-99. doi: 10.1038/s41586-020-2814-7 [published Online First: 2020/09/30]
24. Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med* 2020;383(25):2439-50. doi: 10.1056/NEJMoa2027906 [published Online First: 2020/10/14]
25. Jurgens G. Low dose regimens of BNT162b2 mRNA vaccine exceed SARS-Cov-2 correlate of protection estimates for symptomatic infection, in those 19-55 years of age. medRxiv, 2021.
26. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *N Engl J Med* 2021;384(19):1824-35. doi: 10.1056/NEJMoa2034201 [published Online First: 2021/01/13]
27. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* 2020;396(10249):467-78. doi: 10.1016/S0140-6736(20)31604-4 [published Online First: 2020/07/20]

- 1 28. States FaDAotU. Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab.  
2 Silver Springs, MD, USA: Food and Drug Administration of the United States of America,  
3 2021.
- 4 29. States FaDAotU. Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. In:  
5 States FaDAotU, ed. Silver Springs, MD, USA, 2021.
- 6 30. States FaDAotU. Emergency Use Authorization (EUA) for Sotrovimab. In: States FaDAotU,  
7 ed. Silver Springs, MD, USA, 2021.
- 8 31. Dodds MG, Krishna R, Goncalves A, et al. Model-informed drug repurposing: Viral kinetic  
9 modelling to prioritize rational drug combinations for COVID-19. *Br J Clin Pharmacol*  
10 2020 doi: 10.1111/bcp.14486 [published Online First: 2020/07/21]
- 11 32. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim  
12 WHO Solidarity Trial Results. *N Engl J Med* 2021;384(6):497-511. doi:  
13 10.1056/NEJMoa2023184 [published Online First: 2020/12/02]
- 14 33. RECOVERY. Casirivimab and imdevimab in patients admitted to hospital with COVID-19  
15 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv, 2021.
- 16 34. Bariola JR, McCreary EK, Wadas RJ, et al. Impact of bamlanivimab monoclonal antibody  
17 treatment on hospitalization and mortality among non-hospitalized adults with SARS-  
18 CoV-2 infection. *Open Forum Infectious Diseases* 2021 doi: 10.1093/ofid/ofab254
- 19 35. Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic  
20 Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-  
21 analysis. *JAMA* 2020 doi: 10.1001/jama.2020.17023 [published Online First:  
22 2020/09/02]
- 23 36. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients  
24 with Covid-19. *N Engl J Med* 2021;384(3):229-37. doi: 10.1056/NEJMoa2029849  
25 [published Online First: 2020/10/28]
- 26 37. Mateus J, Dan JM, Zhang Z, et al. Low-dose mRNA-1273 COVID-19 vaccine generates  
27 durable memory enhanced by cross-reactive T cells. *Science* 2021:eabj9853. doi:  
28 10.1126/science.abj9853 [published Online First: 20210914]
- 29 38. Strohbehn GW, Parker WF, A T. What's the right dose for COVID boosters?  
30 MedPageToday2021 [Available from: [https://www.medpagetoday.com/opinion/second-](https://www.medpagetoday.com/opinion/second-opinions/94500)  
31 [opinions/94500](https://www.medpagetoday.com/opinion/second-opinions/94500) accessed October 1 2021.
- 32 39. Wiecek W, Ahuja A, Chaudhuri E, et al. Testing fractional doses of COVID-19 vaccines. *Proc*  
33 *Natl Acad Sci U S A* 2022;119(8) doi: 10.1073/pnas.2116932119 [published Online First:  
34 2022/02/09]
- 35 40. Cowling BJ, Lim WW, Cobey S. Fractionation of COVID-19 vaccine doses could extend limited  
36 supplies and reduce mortality. *Nat Med* 2021 doi: 10.1038/s41591-021-01440-4  
37 [published Online First: 20210705]
- 38 41. Lesko LJ, Rowland M, Peck CC, et al. Optimizing the science of drug development:  
39 opportunities for better candidate selection and accelerated evaluation in humans. *J*  
40 *Clin Pharmacol* 2000;40(8):803-14. doi: 10.1177/00912700022009530
- 41 42. Saad-Roy CM, Morris SE, Metcalf CJ, et al. Epidemiological and evolutionary considerations  
42 of SARS-CoV-2 vaccine dosing regimes. *Science* 2021;372(6540):363-70. doi:  
43 10.1126/science.abg8663 [published Online First: 20210309]

- 1  
2  
3 1 43. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19  
4 2 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national  
5 3 prospective cohort study. *Lancet* 2021 doi: 10.1016/S0140-6736(21)00677-2 [published  
6 4 Online First: 2021/04/23]  
7 5  
8 5 44. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in  
9 6 England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a  
10 7 prospective, multicentre, cohort study. *Lancet* 2021 doi: 10.1016/S0140-6736(21)00790-  
11 8 X [published Online First: 2021/04/23]  
12 9  
13 9 45. Romero-Brufau S, Chopra A, Ryu AJ, et al. Public health impact of delaying second dose of  
14 10 BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.  
15 11 *BMJ* 2021;373:n1087. doi: 10.1136/bmj.n1087 [published Online First: 2021/05/12]  
16 12  
17 12 46. Cobey S, Larremore DB, Grad YH, et al. Concerns about SARS-CoV-2 evolution should not  
18 13 hold back efforts to expand vaccination. *Nat Rev Immunol* 2021 doi: 10.1038/s41577-  
19 14 021-00544-9 [published Online First: 2021/04/01]  
20 15  
21 15 47. Cobey S, Larremore DB, Grad YH, et al. Concerns about SARS-CoV-2 evolution should not  
22 16 hold back efforts to expand vaccination. *Nat Rev Immunol* 2021;21(5):330-35. doi:  
23 17 10.1038/s41577-021-00544-9 [published Online First: 2021/04/03]  
24 18  
25 18 48. Wu JT, Peak CM, Leung GM, et al. Fractional dosing of yellow fever vaccine to extend  
26 19 supply: a modelling study. *Lancet* 2016;388(10062):2904-11. doi: 10.1016/S0140-  
27 20 6736(16)31838-4 [published Online First: 2016/11/14]  
28 21  
29 22 49. Riley S, Wu JT, Leung GM. Optimizing the dose of pre-pandemic influenza vaccines to reduce  
30 23 the infection attack rate. *PLoS Med* 2007;4(6):e218. doi: 10.1371/journal.pmed.0040218  
31 24 [published Online First: 2007/06/21]  
32 25  
33 25 50. Azman AS, Luquero FJ, Ciglenecki I, et al. The Impact of a One-Dose versus Two-Dose Oral  
34 26 Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. *PLoS Med*  
35 27 2015;12(8):e1001867. doi: 10.1371/journal.pmed.1001867 [published Online First:  
36 28 2015/08/26]  
37 29  
38 29 51. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective  
39 30 correlate for COVID-19 vaccines. *Vaccine* 2021;39(32):4423-28. doi:  
40 31 10.1016/j.vaccine.2021.05.063 [published Online First: 2021/07/03]  
41 32  
42 32 52. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-  
43 33 1273 COVID-19 vaccine efficacy clinical trial. *Science* 2022;375(6576):43-50. doi:  
44 34 10.1126/science.abm3425 [published Online First: 2021/11/24]  
45 35  
46 35 53. Laterre PF, Berry SM, Blemings A, et al. Effect of Selepressin vs Placebo on Ventilator- and  
47 36 Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized  
48 37 Clinical Trial. *JAMA* 2019;322(15):1476-85. doi: 10.1001/jama.2019.14607  
49 38  
50 38 54. Berry SM, Spinelli W, Littman GS, et al. A Bayesian dose-finding trial with adaptive dose  
51 39 expansion to flexibly assess efficacy and safety of an investigational drug. *Clin Trials*  
52 40 2010;7(2):121-35. doi: 10.1177/1740774510361541 [published Online First:  
53 41 2010/03/25]  
54 42  
55 42 55. Quartagno M, Carpenter JR, Walker AS, et al. The DURATIONS randomised trial design:  
56 43 Estimation targets, analysis methods and operating characteristics. *Clin Trials*  
57 44 2020;17(6):644-53. doi: 10.1177/1740774520944377 [published Online First:  
58 2020/11/07]  
59  
60

- 1  
2  
3 1 56. Quartagno M, Walker AS, Carpenter JR, et al. Rethinking non-inferiority: a practical trial  
4 2 design for optimising treatment duration. *Clin Trials* 2018;15(5):477-88. doi:  
5 3 10.1177/1740774518778027 [published Online First: 2018/06/07]  
6 4  
7 4 57. Persad GC, Emanuel EJ. The ethics of expanding access to cheaper, less effective  
8 5 treatments. *Lancet* 2016;388(10047):932-4. doi: 10.1016/S0140-6736(15)01025-9  
9 6 [published Online First: 2016/04/20]  
10 7  
11 7 58. Nuzzo JB, Borio LL, Gostin LO. The WHO Declaration of Monkeypox as a Global Public Health  
12 8 Emergency. *JAMA* 2022;328(7):615-17. doi: 10.1001/jama.2022.12513 [published Online  
13 9 First: 2022/07/28]  
14 10  
15 10 59. Branswell H. NYC will use a one-dose monkeypox vaccine strategy to stretch supplies,  
16 11 despite FDA, CDC warnings against the move STAT+2022 [updated July 15, 2022.  
17 12 Available from: [https://www.statnews.com/2022/07/15/nyc-one-dose-monkeypox-](https://www.statnews.com/2022/07/15/nyc-one-dose-monkeypox-strategy-cdc-fda-warnings-against/)  
18 13 [strategy-cdc-fda-warnings-against/](https://www.statnews.com/2022/07/15/nyc-one-dose-monkeypox-strategy-cdc-fda-warnings-against/) accessed August 23 2022.  
19 14  
20 14 60. Branswell H. U.S. moves to stretch out supplies of monkeypox vaccine STAT+2022 [updated  
21 15 August 9, 2022. Available from: [https://www.statnews.com/2022/08/09/u-s-moves-to-](https://www.statnews.com/2022/08/09/u-s-moves-to-stretch-out-supplies-of-monkeypox-vaccine/)  
22 16 [stretch-out-supplies-of-monkeypox-vaccine/](https://www.statnews.com/2022/08/09/u-s-moves-to-stretch-out-supplies-of-monkeypox-vaccine/) accessed August 23 2022.  
23 17  
24 17 61. Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified  
25 18 vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of  
26 19 administration in healthy vaccinia-naive subjects. *Vaccine* 2015;33(39):5225-34. doi:  
27 20 10.1016/j.vaccine.2015.06.075 [published Online First: 2015/07/06]  
28 21  
29 21 62. Krause P, Borio LL. Will low-dose vaccination stretch the monkeypox vaccine supply, or  
30 22 backfire? STAT+2022 [updated August 9, 2022. Available from:  
31 23 [https://www.statnews.com/2022/08/09/will-low-dose-vaccination-stretch-the-](https://www.statnews.com/2022/08/09/will-low-dose-vaccination-stretch-the-monkeypox-vaccine-supply-or-backfire/)  
32 24 [monkeypox-vaccine-supply-or-backfire/](https://www.statnews.com/2022/08/09/will-low-dose-vaccination-stretch-the-monkeypox-vaccine-supply-or-backfire/) accessed August 23 2022.  
33 25  
34 25 63. Branswell H. With monkeypox vaccine in high demand, NIH to test approaches to stretch  
35 26 supplies STAT+2022 [updated August 4, 2023. Available from:  
36 27 [https://www.statnews.com/2022/08/04/with-monkeypox-vaccine-in-high-demand-nih-](https://www.statnews.com/2022/08/04/with-monkeypox-vaccine-in-high-demand-nih-to-test-approaches-to-stretch-supplies/)  
37 28 [to-test-approaches-to-stretch-supplies/](https://www.statnews.com/2022/08/04/with-monkeypox-vaccine-in-high-demand-nih-to-test-approaches-to-stretch-supplies/) accessed August 23 2022.  
38 29  
39 29 64. ClinicalTrials.gov. Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the  
40 30 MVA-BN Monkeypox Vaccine. ClinicalTrials.gov Identifier: NCT05512949.  
41 31 ClinicalTrials.gov2022 [updated August 23, 2022; cited 2022 August 23]. Available from:  
42 32 <https://clinicaltrials.gov/ct2/show/NCT05512949> accessed August 23 2022.  
43 33  
44 33 65. Serritella AV, Strohbehn GW, Goldstein DA, et al. Interventional Pharmacoeconomics: A  
45 34 Novel Mechanism for Unlocking Value. *Clin Pharmacol Ther* 2020 doi: 10.1002/cpt.1853  
46 35 [published Online First: 2020/04/16]  
47 36  
48 37  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 Table and Figure Legends**  
4 **2**

5 **3 Table 1. Dose optimization of repurposed and new molecular entities for SARS-CoV-2 and COVID-19 as of**  
6 **4 Summer 2021.** Drugs that have received regulatory approval or authorization, as well as U.S. guideline-  
7 **5** recommended drugs, for the prevention or treatment of COVID-19 are summarized in the table. From left to right,  
8 **6** columns demonstrate minimal pre-RCT dose-finding in COVID-19, a limited number of welfare-maximizing dose  
9 **7** optimization trials, and the absence of any MDSE identification in COVID-19 therapeutics. **Abbreviations:** RCT,  
10 **8** randomized, controlled trial; MDSE, minimum dose with satisfactory efficacy; IL-6, interleukin-6; CAR-T CRS,  
11 **9** chimeric antigen T-cell receptor-related cytokine release syndrome; EMA, European Medicines Agency; JAK, Janus  
12 **10** kinase; STAT, signal transducer and activator of transcription proteins; ARDS, acute respiratory distress syndrome.  
13

14 **11**  
15 **12 Figure 1. Distinctions between individually and socially optimal dosing approaches for a hypothetical vaccine. (A)**  
16 **13** A randomized dose-finding study reveals the dose-response curve shown, where a vaccine is found to have  
17 **14** maximal efficacy at a 100mcg dose and approximately 75% relative efficacy at quarter-dose. (B) By evaluating the  
18 **15** drug's efficacy relative to the amount of drug administered, we derive the socially optimal dose, maximizing the  
19 **16** efficacy gained per microgram administered. Abbreviations: MDSE, minimum dose with satisfactory efficacy; RCT,  
20 **17** randomized, controlled trial.  
21 **18**




Figure 1

158x237mm (150 x 150 DPI)